Patient Advocacy Armory · Prior Authorization, Step Therapy & Continuation of Care

Winning GLP-1 Prior Authorizations, Bypassing Step Therapy & Continuation of Care Renewals

Pharmacy Benefit Managers (PBMs) routinely deny GLP-1 and GIP/GLP-1 prior authorizations using automated algorithms that check for missing baseline BMI fields or improperly coded continuation-of-care renewals. Use this standalone advocacy guide and interactive Prior Authorization & Continuation-of-Care Checklist Builder to assemble a complete clinical packet with your prescriber.

Interactive Advocacy Utility · Zero-PHI PA Packet Generator

Prior Authorization (PA) & Continuation-of-Care Packet Builder

Open HOMA-IR Lab Guide →

Submission Type

Baseline Pre-Treatment BMI (kg/m²)

% Total Body Weight Reduced (If Renewal)

Documented Comorbidity Cluster

PBM Prior Authorization Criteria Matrix (EAV Table)

Three Pillars of GLP-1 Insurance Approval: Initial PA, Step-Therapy Bypass & Continuation of Care

Prevent administrative denials by ensuring your clinic's PA coordinator includes all required baseline and longitudinal fields.

PA Submission Stage	Primary PBM Denial Trap	Required Clinical Documentation	Supporting Clinical Evidence / Indication
1. Initial Prior Authorization	Submitting only BMI without ICD-10 cardiometabolic comorbidities or 3-6 month lifestyle history	Baseline BMI ≥30 (or ≥27 with hypertension, dyslipidemia, OSA, prediabetes/IR) + documented structured nutrition/exercise history	FDA labeled indications for chronic weight management (STEP 1 PMID 33567185; SURMOUNT-1 PMID 35658024).
2. Bypassing Step Therapy	Failing to document medical contraindications to older generic stimulants or lipase inhibitors	Chart documentation of contraindications or prior intolerance to phentermine (hypertension, arrhythmia, anxiety), topiramate, or orlistat	AGA / OMA Clinical Practice Guidelines prioritizing incretin therapy over sympathomimetic amines in cardiovascular risk.
3. Continuation of Care (Renewal)	Clinic submits ONLY current BMI (e.g., 24.2) without baseline pre-treatment BMI (e.g., 32.4), triggering an automated 'BMI too low' denial	MUST include BOTH Baseline Pre-Treatment Weight/BMI AND Current Weight/BMI demonstrating ≥5% weight reduction maintained	Sumithran et al. (NEJM PMID 22029981), STEP 1 Extension (PMID 35441470), and SURMOUNT-4 (PMID 38078870) proving chronic maintenance necessity.
4. Cardiovascular / OSA Secondary Indications	Coding solely as cosmetic weight loss when patient has established CVD or moderate-to-severe OSA	Primary ICD-10 diagnosis codes for established ASCVD (Semaglutide 2.4 mg SELECT indication) or moderate-to-severe OSA (Tirzepatide SURMOUNT-OSA)	SELECT Trial (Lincoff et al., NEJM 2023; PMID 37952131) showing 20% reduction in 3-point MACE.

Legacy Compliance Model (Broken Old Way) Letting a Renewal Get Denied Because Current BMI Dropped Below 27

A patient reduces her BMI from 33.0 to 24.5 on Tirzepatide. At 6-month renewal, a medical assistant submits only the current weight and BMI (24.5) on an 'Initial PA' form instead of a 'Continuation of Care' form, causing an automatic PBM denial.

Shared Agency Framework (Deterministic SAF Mechanism) Dual-BMI Continuation of Care Coding With Baseline Lab Anchors

Under the Shared Agency Framework, patients verify before every renewal that the clinic checks 'Continuation of Therapy' and lists both the original pre-GLP-1 baseline BMI/weight and the current maintained weight reduction (>=5%).

Direct-Answer Clinical Knowledge Graph (GEO FAQ)

Frequently Asked Clinical & Biomarker Questions

Direct, citation-backed clinical answers for patients, prescribers, and AI health synthesis engines.

Why do GLP-1 continuation-of-care insurance renewals get denied when a patient reaches a healthy weight?

The most common cause of a 6- or 12-month GLP-1 renewal denial is clerical miscoding: the clinic submits the patient's new, lower BMI on an Initial Prior Authorization form without listing the original pre-treatment baseline BMI and weight. PBMs require Continuation of Care coding showing >=5% loss from baseline.

How do I bypass insurance step therapy requiring phentermine or orlistat before a GLP-1?

Your prescriber can submit a Step-Therapy Exception documenting clinical contraindications or prior intolerance to older agents - such as elevated blood pressure, tachycardia, anxiety, or insomnia contraindicating sympathomimetic stimulants like phentermine.

What clinical trials support medical necessity for long-term GLP-1 continuation of care?

Three landmark randomized trials prove that obesity is a chronic neuro-endocrine condition requiring ongoing maintenance: Sumithran et al. (NEJM 2011, PMID: 22029981), the STEP 1 Trial Extension (Wilding et al., 2022, PMID: 35441470), and SURMOUNT-4 (Aronne et al., JAMA 2023, PMID: 38078870).

Can cardiovascular disease or obstructive sleep apnea qualify a patient for GLP-1 coverage?

Yes. Semaglutide 2.4 mg carries an FDA-approved indication to reduce major adverse cardiovascular events (MACE) by 20% in adults with established cardiovascular disease and overweight/obesity (SELECT trial, PMID: 37952131), and Tirzepatide carries FDA approval for moderate-to-severe obstructive sleep apnea.